Results for promielocitno translation from Slovenian to English

učinkovitosti in varnosti zdravila dacogen pri bolnikih z akutno promielocitno levkemijo ali z levkemijo centralnega živčevja niso ocenjevali.
the efficacy and safety of dacogen has not been evaluated in patients with acute promyelocytic leukaemia or cns leukaemia.

bolniki z akutno promielocitno levkemijo se navadno zdravijo z retinoidi (snovmi, pridobljenimi iz vitamina a).
patients with apl are normally treated with retinoids (substances derived from vitamin a).

zdravilo trisenox se uporablja pri bolnikih z akutno promielocitno levkemijo (apl), pri katerih druge oblike zdravljenja niso pomagale.
trisenox is used in patients with acute promyelocytic leukaemia (apl) whose disease has not responded to other therapies.

zdravilo trisenox se uporablja pri odraslih bolnikih z akutno promielocitno levkemijo (apl), pri katerih druge oblike zdravljenja niso pomagale.
trisenox is used in adult patients with acute promyelocytic leukaemia (apl) whose disease has not responded to other therapies.

arzenov trioksid povzroča tudi poškodbe in razgradnjo fuzijske beljakovine receptorja za promielocitno levkemijo/retinojsko kislino alfa (pml/rar-alfa).
arsenic trioxide also causes damage or degradation of the fusion protein pro-myelocytic leukaemia/retinoic acid receptor-alpha (pml/rar alpha).

zdravilo trisenox je indicirano za indukcijo remisije in konsolidacije pri odraslih bolnikih z akutno promielocitno levkemijo (apl – »acute promyelocytic leukaemia«) v relapsu ali refraktarni fazi, za katero je značilna prisotnost translokacije t(15;17) in/ali prisotnost gena za receptor za promielocitno levkemijo/retinojsko kislino alfa (pml/rar-alfa).
trisenox is indicated for induction of remission and consolidation in adult patients with relapsed/refractory acute promyelocytic leukaemia (apl), characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor- alpha (pml/rar-alpha) gene.